Caribou Biosciences Inc (CRBU)
1.76
-0.11
(-5.88%)
USD |
NASDAQ |
Jun 25, 16:00
1.75
-0.01
(-0.57%)
After-Hours: 20:00
Caribou Biosciences Total Liabilities (Quarterly): 63.54M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 63.54M |
| December 31, 2023 | 63.81M |
| September 30, 2023 | 59.25M |
| June 30, 2023 | 80.19M |
| March 31, 2023 | 69.19M |
| December 31, 2022 | 72.89M |
| September 30, 2022 | 74.71M |
| Date | Value |
|---|---|
| June 30, 2022 | 73.48M |
| March 31, 2022 | 74.20M |
| December 31, 2021 | 54.53M |
| September 30, 2021 | 57.56M |
| June 30, 2021 | 206.09M |
| March 31, 2021 | 203.65M |
| December 31, 2020 | 59.48M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
54.53M
Minimum
Dec 2021
206.09M
Maximum
Jun 2021
86.61M
Average
71.04M
Median
Total Liabilities (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 7.378B |
| Sangamo Therapeutics Inc | 72.26M |
| Vertex Pharmaceuticals Inc | 5.371B |
| Bio-Path Holdings Inc | 4.393M |
| Revance Therapeutics Inc | 606.79M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 406.82M |
| Shareholders Equity (Quarterly) | 343.29M |
| Current Ratio | 10.49 |